Eisai's Etalanetug Shows Significant Reduction in Alzheimer's Tau Biomarker
Event summary
- Eisai's investigational anti-tau antibody etalanetug reduced plasma eMTBR-tau243 biomarker by 78% at 3 months and over 90% at 9 months in DIAD patients.
- The Phase Ib/II Study 103 showed etalanetug also reduced CSF eMTBR-tau243 by 62% at 3 months and 89% at 9 months.
- Plasma eMTBR-tau243 is proposed as a less invasive alternative to CSF and PET testing for Alzheimer's disease pathology.
- Etalanetug received Fast Track designation from the FDA in September 2025.
The big picture
Eisai's findings position etalanetug as a potential breakthrough in targeting tau pathology, a key driver of Alzheimer's progression. The results support the growing trend toward biomarker-driven drug development and combination therapies in neurodegenerative diseases. With Fast Track designation secured, Eisai is well-positioned to accelerate clinical validation in both dominantly inherited and sporadic forms of Alzheimer's.
What we're watching
- Clinical Validation
- Whether the biomarker reductions translate to meaningful cognitive improvements in later-stage trials.
- Regulatory Pathway
- The pace at which Eisai advances etalanetug through Phase II/III studies and potential FDA approval.
- Combination Therapy
- How the addition of etalanetug to lecanemab impacts treatment outcomes in sporadic Alzheimer's disease.
Related topics